Although we have preliminarily explored the molecular mechanism of H19 regulating the matrix mineralization of osteoblasts in vitro, further in vivo experiments are needed to verify the feasibility of H19 as a potential therapeutic target for skeletal diseases in future studies. This evidence concerns the gene H19 and bone disorder.